Form 8.5 (EPT/RI)- Replacement of Dechra

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.

Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy

To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.

(a) Name of exempt principal trader:	Morgan Stanley & Co. International plc
(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree	Dechra Pharmaceuticals plc
(c) Name of the party to the offer with which exempt principal trader is connected:	EQT (EQT X EUR SCSp and EQT X USD SCSp)
(d) Date dealing undertaken:	08 December 2023
(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer? If it is a cash offer or possible cash offer, state "N/A"	N/A

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
1p ordinary	CFD	increasing a long position	830	38.3200 GBP
1p ordinary	CFD	increasing a long position	55	38.3400 GBP
1p ordinary	CFD	increasing a long position	83	38.3487 GBP
1p ordinary	CFD	increasing a long position	87	38.3488 GBP
1p ordinary	CFD	increasing a long position	141	38.3500 GBP
1p ordinary	CFD	increasing a long position	22,113	38.3581 GBP
1p ordinary	CFD	increasing a short position	329	38.3200 GBP
1p ordinary	CFD	increasing a short position	1,141	38.3200 GBP
1p ordinary	CFD	increasing a short position	22	38.3202 GBP
1p ordinary	CFD	increasing a short position	897	38.3260 GBP
1p ordinary	CFD	increasing a short position	1,941	38.3400 GBP
1p ordinary	CFD	increasing a short position	1,401	38.3427 GBP
1p ordinary	CFD	increasing a short position	106	38.2800 GBP
1p ordinary	CFD	reducing a long position	402	38.3200 GBP
1p ordinary	CFD	reducing a long position	1,776	38.3382 GBP
1p ordinary	CFD	reducing a long position	99	38.3437 GBP
1p ordinary	CFD	reducing a long position	4	38.3500 GBP
1p ordinary	CFD	reducing a short position	978	38.3349 GBP
1p ordinary	CFD	reducing a short position	292	38.3400 GBP
1p ordinary	CFD	reducing a short position	106	38.3400 GBP

Date of disclosure:	12 December 2023
Contact name:	Craig Horsley
Telephone number:	+44 141 245-7736

Date of disclosure:

Contact name:

Telephone number:

Companies

UK 100

Latest directors dealings